Loading
NASDAQHealthcareBiotechnology
Latest quote
$23.81
+$1.24 · +5.49%
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Previous close
$23.81
+$1.24 · +5.49%
Regular session · ET · Market data may be delayed.
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Day range
Current $23.81
52-week range
Current $23.81
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
57
Fair Value
Sentiment
70
Bullish
Risk
44
Elevated Risk
Momentum
71
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Day range
Current $23.81
52-week range
Current $23.81
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 62.38M USD | 42.07M USD | 36.53M USD | 24.86M USD | 37.04M USD |
| Cost of goods sold | 2.28M USD | — | — | — | — |
| Gross profit | 60.1M USD | 42.07M USD | 36.53M USD | 24.86M USD | 37.04M USD |
| Research and development | 132.17M USD | 143.92M USD | 115.2M USD | 105.91M USD | 77.64M USD |
| Selling, general, and administrative | 41.51M USD | 43.75M USD | 35.5M USD | 30.03M USD | 17.6M USD |
| Operating expenses | 171.39M USD | 187.66M USD | 150.7M USD | 135.93M USD | 95.23M USD |
| Interest income | 5.63M USD | 7.89M USD | 6.62M USD | 1.46M USD | 495K USD |
| Depreciation and amortization | 2.28M USD | 2.5M USD | 2.42M USD | 1.61M USD | 897K USD |
| Operating income | −111.29M USD | −145.6M USD | −114.17M USD | −111.07M USD | −58.19M USD |
| Net income | −101.59M USD | −130.3M USD | −101.74M USD | −108.18M USD | −58.24M USD |
Company facts updated Oct 11, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$45.91
92.82% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI100.62M0.00%2.3T USD0.03%$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI92.98M0.94%9.87B USD0.35%$153.77+3.00%
iShares Russell 2000 ETFIWM83.75M0.11%78.74B USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF32.84M0.03%95.4B USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO29.37M0.21%13.92B USD0.24%$356.78+0.94%
iShares Biotechnology ETFIBB24.38M0.23%10.82B USD0.44%$206.49+3.00%
Vanguard Russell 2000 ETFVTWO18.49M0.10%18B USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA17.32M0.08%21.82B USD0.03%$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
